Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
- PMID: 17652805
- DOI: 10.1007/s12012-007-0016-2
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
Abstract
The clinical manifestations of anti-cancer drug associated cardiac side effects are diverse and can range from acutely induced cardiac arrhythmias to Q-T interval prolongation, changes in coronary vasomotion with consecutive myocardial ischemia, myocarditis, pericarditis, severe contractile dysfunction, and potentially fatal heart failure. The pathophysiology of these adverse effects is similarly heterogeneous and the identification of potential mechanisms is frequently difficult since the majority of cancer patients is not only treated with a multitude of cancer drugs but might also be exposed to potentially cardiotoxic radiation therapy. Some of the targets inhibited by new anti-cancer drugs also appear to be important for the maintenance of cellular homeostasis of normal tissue, in particular during exposure to cytotoxic chemotherapy. If acute chemotherapy-induced myocardial damage is only moderate, the process of myocardial remodeling can lead to progressive myocardial dysfunction over years and eventually induce myocardial dysfunction and heart failure. The tools for diagnosing anti-cancer drug associated cardiotoxicity and monitoring patients during chemotherapy include invasive and noninvasive techniques as well as laboratory investigations and are mostly only validated for anthracycline-induced cardiotoxicity and more recently for trastuzumab-associated cardiac dysfunction.
Similar articles
-
Exposure to anthracyclines during childhood causes cardiac injury.Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019. Semin Oncol. 2006. PMID: 16781284 Review.
-
Anthracycline-induced cardiomyopathy.Postgrad Med. 2008 Nov;120(4):67-72. doi: 10.3810/pgm.2008.11.1940. Postgrad Med. 2008. PMID: 19020367 Review.
-
[Chemotherapeutics-induced heart failure].Med Klin (Munich). 2007 Jul 15;102(7):574-8. doi: 10.1007/s00063-007-1071-y. Med Klin (Munich). 2007. PMID: 17634876 Review. German.
-
Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.Pediatr Blood Cancer. 2005 Jun 15;44(7):600-6. doi: 10.1002/pbc.20352. Pediatr Blood Cancer. 2005. PMID: 15856486 Review.
-
[Cardiotoxicity of anthracyclines].Rev Med Chir Soc Med Nat Iasi. 2011 Oct-Dec;115(4):1200-7. Rev Med Chir Soc Med Nat Iasi. 2011. PMID: 22276470 Romanian.
Cited by
-
The anthracyclines: when good things go bad.Cardiovasc Toxicol. 2007;7(2):53-5. doi: 10.1007/s12012-007-0017-1. Cardiovasc Toxicol. 2007. PMID: 17652803 Free PMC article.
-
Ionizing radiation regulates cardiac Ca handling via increased ROS and activated CaMKII.Basic Res Cardiol. 2013 Nov;108(6):385. doi: 10.1007/s00395-013-0385-6. Epub 2013 Sep 26. Basic Res Cardiol. 2013. PMID: 24068185 Free PMC article.
-
Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib.Breast Care (Basel). 2008;3(s1):13-16. doi: 10.1159/000119748. Epub 2008 Apr 24. Breast Care (Basel). 2008. PMID: 20824003 Free PMC article. No abstract available.
-
Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Am J Transl Res. 2016 Jul 15;8(7):2862-75. eCollection 2016. Am J Transl Res. 2016. PMID: 27508008 Free PMC article. Review.
-
Systems analysis of miRNA biomarkers to inform drug safety.Arch Toxicol. 2021 Nov;95(11):3475-3495. doi: 10.1007/s00204-021-03150-9. Epub 2021 Sep 12. Arch Toxicol. 2021. PMID: 34510227 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical